Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
eythrocytapheresis, whole blood collection · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| eythrocytapheresis | PROCEDURE | machinal collection of erythrocytes |
| whole blood collection | PROCEDURE | collection of whole blood |
Inclusion Criteria: * Elective surgery Exclusion Criteria: * Malignancies * Severe arrhythmias * Congestive heart failure * Recent angina * Epileptic seizures in the last 3 months before collection
Eythrocytapheresis, whole blood collection is used for pre operative autologous donation, a procedure in which a patient's own blood is collected before surgery for later transfusion. It is being studied in a Phase 3 clinical trial in the Netherlands.
Atrium Therapeutics, Inc. is developing eythrocytapheresis, whole blood collection. The company's ticker symbol is RNA.
Eythrocytapheresis, whole blood collection is in Phase 3 clinical development. It is an investigational procedure and has not been approved by the FDA.
Eythrocytapheresis, whole blood collection is being studied in the clinical trial NCT00202475, titled 'Collection of Autologous Blood Products by Double Erythrocytapheresis'. This Phase 3 trial has been completed and enrolled 100 participants in the Netherlands.
Eythrocytapheresis, whole blood collection is studied in a trial titled 'Collection of Autologous Blood Products by Double Erythrocytapheresis', which involves the collection of autologous blood products. The procedure is used for pre operative autologous donation.